Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver?
Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Cancer Treatment and Research Communications (2021) Vol. 27, pp. 100356-100356
Open Access | Times Cited: 25

Showing 25 citing articles:

Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians
Demetrios Moris, Manisha Palta, Charles Kim, et al.
CA A Cancer Journal for Clinicians (2022) Vol. 73, Iss. 2, pp. 198-222
Open Access | Times Cited: 282
Cholangiocarcinoma: Recent Advances in Molecular Pathobiology and Therapeutic Approaches
Divya Khosla, Shagun Misra, Pek Lim Chu, et al.
Cancers (2024) Vol. 16, Iss. 4, pp. 801-801
Open Access | Times Cited: 17
Treatment of Intrahepatic Cholangiocarcinoma—A Multidisciplinary Approach
Felix Krenzien, Nora Nevermann, Alina Krombholz, et al.
Cancers (2022) Vol. 14, Iss. 2, pp. 362-362
Open Access | Times Cited: 54
Up-to-Date Pathologic Classification and Molecular Characteristics of Intrahepatic Cholangiocarcinoma
Taek Chung, Young Nyun Park
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 51
Clinical management of intrahepatic cholangiocarcinoma: surgical approaches and systemic therapies
Samantha M. Ruff, Timothy M. Pawlik
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 12
Practical guidelines for molecular testing of cholangiocarcinoma in clinical practice: Italian experts’ position paper
Matteo Fassan, Valentina Angerilli, Nicola Normanno, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 194, pp. 104224-104224
Open Access | Times Cited: 7
Tubulocystic Carcinoma of Bile Ducts
Francesca Masetto, Andrea Mafficini, Burcu Saka, et al.
The American Journal of Surgical Pathology (2024) Vol. 48, Iss. 9, pp. 1082-1092
Closed Access | Times Cited: 5
Cancer Therapy Guided by Mutation Tests: Current Status and Perspectives
Svetlana N. Aleksakhina, Evgeny N. Imyanitov
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 20, pp. 10931-10931
Open Access | Times Cited: 31
Current status and prospects of targeted therapy for cholangiocarcinoma based on molecular characteristics
Xiaoqiang Cui, Teng Huang, Tianyi Jiang, et al.
Cancer Letters (2025) Vol. 614, pp. 217540-217540
Closed Access
Development of Novel Epigenetic Anti-Cancer Therapy Targeting TET Proteins
Hyejin Kim, Inkyung Jung, Chan Hyeong Lee, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 22, pp. 16375-16375
Open Access | Times Cited: 8
Precision Medicine in Cholangiocarcinoma: Past, Present, and Future
Chi-Yuan Cheng, Chiao‐Ping Chen, Chiao‐En Wu
Life (2022) Vol. 12, Iss. 6, pp. 829-829
Open Access | Times Cited: 12
Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors
Alessandro Rizzo
Medicina (2021) Vol. 57, Iss. 5, pp. 458-458
Open Access | Times Cited: 13
The Role of the Hedgehog Pathway in Cholangiocarcinoma
Giulia Anichini, Laura Carrassa, Barbara Stecca, et al.
Cancers (2021) Vol. 13, Iss. 19, pp. 4774-4774
Open Access | Times Cited: 12
Method for the Intraoperative Detection of IDH Mutation in Gliomas with Differential Mobility Spectrometry
Ilkka Haapala, Anton Rauhameri, Antti Roine, et al.
Current Oncology (2022) Vol. 29, Iss. 5, pp. 3252-3258
Open Access | Times Cited: 8
Evolving therapeutic landscape of advanced biliary tract cancer: from chemotherapy to molecular targets
Linde Kehmann, Markus S. Jördens, S Loosen, et al.
ESMO Open (2024) Vol. 9, Iss. 10, pp. 103706-103706
Open Access | Times Cited: 1
Therapeutic vulnerabilities and pan-cancer landscape of BRAF class III mutations in epithelial solid tumors
Eylül Özgü, Benjamin G. Kaplan, Smruthy Sivakumar, et al.
BJC Reports (2024) Vol. 2, Iss. 1
Open Access | Times Cited: 1
Cognitive and ataxic adverse events following entrectinib treatment in NTRK1 fusion gene-positive intrahepatic cholangiocarcinoma: a case report
Kazuya Koyama, Hidetaka Iwamoto, Kenji Takahashi, et al.
Clinical Journal of Gastroenterology (2024) Vol. 18, Iss. 1, pp. 183-187
Closed Access | Times Cited: 1
Mutation-based therapies for intrahepatic cholangiocarcinoma: new options on the horizon
Si-Yuan Pan, Yu-Hang Ye, Zheng‐Jun Zhou, et al.
Hepatoma Research (2024)
Open Access | Times Cited: 1
Current and Future Therapeutic Targets for Directed Molecular Therapies in Cholangiocarcinoma
Philipp Heumann, Andreas Albert, Karsten Gülow, et al.
Cancers (2024) Vol. 16, Iss. 9, pp. 1690-1690
Open Access | Times Cited: 1
Circulating Oncometabolite 2-hydroxyglutarate as a Potential Biomarker for Isocitrate Dehydrogenase (IDH1/2) Mutant Cholangiocarcinoma
Cha Len Lee, Grainne M. O’Kane, Warren Mason, et al.
Molecular Cancer Therapeutics (2023) Vol. 23, Iss. 3, pp. 394-399
Open Access | Times Cited: 3
Ivosidenib for IDH1 Mutant Cholangiocarcinoma: A Narrative Review
Vikram Sumbly, Ian Landry, Vincent Rizzo
Cureus (2022)
Open Access | Times Cited: 5
Research progress and prospect of postoperative adjuvant therapy for resectable intrahepatic cholangiocarcinoma
Yanxin Sun, Wei Jiang, Ruiheng Duan, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access
Immunotherapy of Biliary Tract Cancer
Joachim C. Mertens, Ralph Fritsch
Cancer immunotherapy (2023), pp. 187-206
Closed Access | Times Cited: 1
Review of IDH mutations and potential therapies for intrahepatic cholangiocarcinoma
Samantha M. Ruff, Mary Dillhoff
Hepatoma Research (2023)
Open Access
Epigenetic therapy and DNA damage response
Marina Baretti, Nilofer S. Azad
Elsevier eBooks (2022), pp. 227-252
Closed Access
Page 1

Scroll to top